Overview

Safety and Efficacy of TOP1630 for Dry Eye Syndrome

Status:
Completed
Trial end date:
2017-06-15
Target enrollment:
Participant gender:
Summary
In subjects with Dry Eye Syndrome: The primary objective of this study is to compare the safety and tolerability of TOP1630 Ophthalmic Solution to placebo. The secondary objectives are to compare the efficacy of TOP1630 Ophthalmic Solution to placebo for the treatment of the signs and symptoms of dry eye syndrome.
Phase:
Phase 2
Details
Lead Sponsor:
Topivert Pharma Ltd
Treatments:
Ophthalmic Solutions
Pharmaceutical Solutions